Ann: iPPS Increases Cartilage Thickness in Phase 2 Trial, page-114

Two positive announcements on trial data and two 20%+ intraday moves that were curtailed by selling. Some very decent volumes gone through on PAR on both announcements. You know from volumes and history most of the selling is likely doing so at a loss recently, unless they bought more than 5 years ago! Good riddance to some larger weak sophisticated/institutional hands that have hopefully all been shaken out at the bottom of a trading/debt cycle that will curtail, just as the silly global central bank fed highs did in late 2021:



Some buyers building some big positions at levels in PAR not seen in over five years. I think we can somewhat confidently say PAR has progressed its business prospects in that time. Have to agree with comments above, bigger pharma' surely looking at PAR's success with such a simple injectable treatment - if they aren't they are not doing their jobs on such a massive addressable market. If PR cannot court a partner on the back of these results, he likewise is not doing his job.